| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/30/2005 | US20050143444 Use of ACE inhibitors for treatment of patients suffering from behavioral disorders |
| 06/30/2005 | US20050143443 4-substituted pyrrole-2-carboxylic acidsand 5-substituted pyrazole-3-carboxylic acids/esters/salts; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia |
| 06/30/2005 | US20050143441 drug mixture including a lipase enzyme inhibitor orlistat |
| 06/30/2005 | US20050143440 Excellent hypoglycemic agents for treating hyperglycemia, dyslipidemia, hypercholesterolemia, noninsulin-dependent type II diabetes, obesity, glucose intolerance, cardiovascular diabetic complications; reduced side effects due to absence of serotonin reuptake inhibition; imidazoline receptor pathologies |
| 06/30/2005 | US20050143438 N3 alkylated benzimidazole derivatives as MEk inhibitors |
| 06/30/2005 | US20050143437 Novel crystal form of 5-hydroxy-1-methylhydantoin |
| 06/30/2005 | US20050143436 N-acylamino with fused nitrogen heterocyclic ring compound; capase enzyme inhibitors; antiinflammatory agents; oral bioavailability; autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases |
| 06/30/2005 | US20050143435 Drug mixture comprising Moxonidine and Eprosartan mesylate for control of blood pressure; hypotensive agents treating type II diabetes, associated with heart failure, or renal impairment; rilmenidine, and candesartan, eprosartan, irbesartan, losartan, olmesartan, pratosartan, telmisartan and valsartan |
| 06/30/2005 | US20050143434 Or Benzo(d)isothiazol-3-ols, O-alkyl derivatives and aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc salts; enhancing learning, memory and/or cognition and treating ataxia, neuropathic pain or for preventing loss of neuronal function characteristic of neurodegenerative diseases |
| 06/30/2005 | US20050143433 Substituted heterocycles useful for treating HCV infection |
| 06/30/2005 | US20050143430 Catechol bioisosteres |
| 06/30/2005 | US20050143429 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 06/30/2005 | US20050143426 Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion |
| 06/30/2005 | US20050143424 antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide |
| 06/30/2005 | US20050143423 Antiulcer; antisecretory; solubility, bioavailability; slow hydrolysis; full inhibition of acid secretion in oral therapy by prolonged presence in body; 1-(carboxythiophenesulfonyl)- 2-(substituted pyridylmethylsulfinyl) benzimidazoles; also with LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, or RABEPRAZOLE |
| 06/30/2005 | US20050143420 administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
| 06/30/2005 | US20050143419 Guanidine and amidine derivatives as factor Xa inhibitors |
| 06/30/2005 | US20050143418 Pesticidal heterocycles |
| 06/30/2005 | US20050143417 Dissolving difloxacin HCl and L-arginine base in a mixture of water, ethanol, propylene glycol, and optionally benzyl alcohol, at a pH of 9 to 10 and at a temperature of 10-30 degrees C.; minimized tissue damage or irritation at the injection site. |
| 06/30/2005 | US20050143416 Salts and polymorphs of a potent antidiabetic compound |
| 06/30/2005 | US20050143415 For the production of a pharmaceutical agent for therapy of inflammatory diseases |
| 06/30/2005 | US20050143412 Controlled cessation of heart beat during cardiac surgeries by electrical stimulation of the vagus nerve and administration of a combination of drugs; improved surgical technique; Controlled intermittent asystole |
| 06/30/2005 | US20050143411 Administering a macrolide such as FK-506 to treat airflow obstruction e.g. induced by cigarette smoke, chronic bronchitis, emphysema or chronic obstructive pulmonary disease |
| 06/30/2005 | US20050143409 Regimen for the administration of rifamycin-class antibiotics |
| 06/30/2005 | US20050143408 Aporphine esters and their use in therapy |
| 06/30/2005 | US20050143405 Dipeptidyl peptidase inhibitors that lower plasma glucose; treatment and prophylaxis of diabetes, non-insulin dependent diabetes; 2-amino-3aminomethyl-4-phenylpyridines |
| 06/30/2005 | US20050143404 Solid pharmaceutical dosage formulation |
| 06/30/2005 | US20050143403 Substituted pyrimidinones and pyrimidinthiones |
| 06/30/2005 | US20050143401 Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine |
| 06/30/2005 | US20050143400 Process for preparing famciclovir |
| 06/30/2005 | US20050143399 Novel compounds |
| 06/30/2005 | US20050143398 mitogen-activated protein (MAP), p38 kinase ( alpha and beta)-associated conditions; antiinflammatory and antidiabetic agent; inflammatory bowel disease, rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, asthma |
| 06/30/2005 | US20050143397 Processes for preparation of ziprasidone |
| 06/30/2005 | US20050143395 (2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-3-yl)-acetaldehyde, and, 3-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-vinyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one; intermediates to risperidone |
| 06/30/2005 | US20050143393 Bactericides; infection therapy; topical administering |
| 06/30/2005 | US20050143392 3,1'-didehydro-3[2"(3'",3'"-dimethyl-prop-2-enyl)-3"-indolyl methylene]-6-methylpiperazine-2,5-dione; Fermentation of a mangrove-associated fungus Penicillium chrysogenum; solvent extraction; antibiotic against Gram-negative Vibrio cholerae; alternative to Tetracycline |
| 06/30/2005 | US20050143390 piperidines or piperazines 1-linked to a 1-(1-carbonylpiperidin-4-yl)piperidinyl- group through an optionally substituted methyl group; treating Human Immuno-deficiency Virus, solid organ transplant rejection, arthritis, rheumatoid arthritis, and multiple sclerosis |
| 06/30/2005 | US20050143389 may be coadministered with an antiviral medication. |
| 06/30/2005 | US20050143388 Nitric oxide donors for treatment of disease and injury |
| 06/30/2005 | US20050143387 Preserving cosmetic, household or technical products, use in paper treatment liquors, printing thickeners, printing thickeners of starch or cellulose derivatives and paints |
| 06/30/2005 | US20050143386 Diagnosis and management of infection caused by Chlamydia |
| 06/30/2005 | US20050143385 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| 06/30/2005 | US20050143384 N-[5-(3,5-Dichloro-2-hydroxy-phenyl)-[1,3,4]thiadiazol-2-yl]-terephthalamic acid; thromboembolic disorder: infarction, ischemia, stroke, atherosclerosis, thrombophlebitis, embolism; mixture with second PAI-1 or factor Xa inhibitors, anti-coagulant, anti-platelet, thrombolytic, and fibrinolytic agents |
| 06/30/2005 | US20050143382 Heterocyclic compounds as pharmaceutically active compounds |
| 06/30/2005 | US20050143381 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 06/30/2005 | US20050143379 Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 06/30/2005 | US20050143378 Treatment of conditions through pharmacological modulation of the autonomic nervous system |
| 06/30/2005 | US20050143377 Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions |
| 06/30/2005 | US20050143376 Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones |
| 06/30/2005 | US20050143373 Benzodioxole derivatives |
| 06/30/2005 | US20050143372 Compounds, pharmaceutical compositions and methods of use therefor |
| 06/30/2005 | US20050143371 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| 06/30/2005 | US20050143370 Therapeutic compounds |
| 06/30/2005 | US20050143368 Chemical compounds |
| 06/30/2005 | US20050143366 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders |
| 06/30/2005 | US20050143364 21-Substituted progesterone derivatives as new antiprogestational agents |
| 06/30/2005 | US20050143363 Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases |
| 06/30/2005 | US20050143362 Danazol for treatment of hypogonadism in the adult male |
| 06/30/2005 | US20050143361 Compositions for pulmonary administration |
| 06/30/2005 | US20050143360 dysmenorrhea; e.g. celecoxib and ethinyl estradiol and levonorgestrel; side effect reduction as lower doses possible |
| 06/30/2005 | US20050143359 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| 06/30/2005 | US20050143358 Methods for reducing body fat using vitamin D compounds |
| 06/30/2005 | US20050143357 Vitamin d upregulated protein 1 (vdup-) methods and uses thereof |
| 06/30/2005 | US20050143356 Selective inhibition of cyclooxygenase 1 in the treatment of diabetic nephropathy |
| 06/30/2005 | US20050143354 Association of an antithrombotic and aspirin |
| 06/30/2005 | US20050143350 Combination drug therapy to treat obesity |
| 06/30/2005 | US20050143349 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels |
| 06/30/2005 | US20050143348 Doxepin analogs and methods of use thereof |
| 06/30/2005 | US20050143347 Medicinal lipolysis of accumulations of fat |
| 06/30/2005 | US20050143346 Blocks the phosphorylation of ceramide and sphingosine, thereby maintaining high concentration of ceramide and sphingosine; has inhibitory activity of sphingosine kinase |
| 06/30/2005 | US20050143344 Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| 06/30/2005 | US20050143343 Nutritional supplement for enhancing the production and effect of natural human growth hormone |
| 06/30/2005 | US20050143342 Administering sulfated polysaccharide such as cellulose sulfate, dextran sulfate, dermatan sulfate, chondroitin sulfate, pentosan sulfate, fucoidin, mannan sulfate, dextrin sulfate, curdlan sulfate, chitin sulfate, heparin or heparin sulfate for therapy and prophylaxis of fungal infection |
| 06/30/2005 | US20050143340 Adenosyl-cobalamin fortified compositions |
| 06/30/2005 | US20050143339 Having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group; also with an esterase inhibitor:increasing the elimination half-life of key metabolites such as d4T; inhibits human immune |
| 06/30/2005 | US20050143337 Nucleic acid-based compounds and methods of use thereof |
| 06/30/2005 | US20050143336 Prevent or reduce inflammation secondary to administration of a lipid-nucleic acid complex in a subject by co-administering a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunosuppressive agent with the lipid-nucleic acid complex |
| 06/30/2005 | US20050143332 Delivering a siRNA to a mammal cell; low toxicity |
| 06/30/2005 | US20050143329 Indole antiviral compositions and methods |
| 06/30/2005 | US20050143328 2-deoxystreptamine aminoglycoside molecules; treatment of DNA-containing envelope virus infections, such as herpes simplex-1 |
| 06/30/2005 | US20050143327 Used to ameliorate oxidative stress diseases eg neurodegenerative diseases |
| 06/30/2005 | US20050143326 antibacterial; substituted methylene in the 11 position |
| 06/30/2005 | US20050143325 Topical invermectin composition |
| 06/30/2005 | US20050143324 Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye |
| 06/30/2005 | US20050143323 Side effect reduction; genistein, daidzein |
| 06/30/2005 | US20050143322 Method for treating obesity |
| 06/30/2005 | US20050143321 Characterized by spontaneous increasing of the redox potential in relation to the potential of the hydrogen electrode; used in food industry, medicine, veterinary medicine, pharmaceutical industry, cosmetic industry, balneology, agriculture, fish farming |
| 06/30/2005 | US20050143320 Protease inhibitors |
| 06/30/2005 | US20050143319 Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome |
| 06/30/2005 | US20050143316 Hepatitis C virus inhibitors |
| 06/30/2005 | US20050143315 N-[5-[[[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride having radiosensitisation activity |
| 06/30/2005 | US20050143314 Compositions and methods to treat recurrent medical conditions |
| 06/30/2005 | US20050143304 Osteogenic protein/bone morphogenetic proteins of eukaryotic origin |
| 06/30/2005 | US20050143288 Use of lipid conjugates in the treatment of diseases |
| 06/30/2005 | US20050143283 with a chelating agent; improves the solution stability; lyophilized; antithrombotic agent |
| 06/30/2005 | US20050142640 MUC-1 derived peptides |
| 06/30/2005 | US20050142628 Use |
| 06/30/2005 | US20050142621 Methods of identifying anti-cancer agents and uses thereof |
| 06/30/2005 | US20050142604 Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210 |
| 06/30/2005 | US20050142601 Nucleic acids encoding an enediyne polyketide synthase complex |